Telehealth Provider Regulatory Timeline 2025-2026
The 2025-2026 period reshaped the telehealth-provider regulatory landscape across multiple categories at once. Two major FDA enforcement waves on compounded GLP-1 (September 2025 and March 2026), a multi-front Eli Lilly lawsuit against compounders, the public Novo Nordisk-Hims dispute and settlement, Novo Nordisk's broader 14-defendant compounded-semaglutide enforcement, a Washington State Notice of Immediate Jeopardy on a compounding pharmacy affiliated with one of the largest compounded-GLP-1 telehealth providers, an industry-wide FDA safety alert on compounded topical finasteride, FDA class-wide labeling changes for testosterone products, and material corporate events at Function Health and Tally Health all happened inside fourteen months. This page is a chronological reference for every event affecting providers in our marketplace cohort, with primary sources for each.
Last reviewed May 1, 2026. Each source URL HEAD-checked at publish time. Subscribe via RSS.
Bottom line
The 2025-2026 enforcement environment hit some providers in our cohort hard (Hims got twin FDA warning letters and a Novo Nordisk lawsuit before settling; Mochi Health's affiliated compounding pharmacy Aequita received a Washington State Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed-worker sterile compounding), affected others through industry-wide actions (Ro flagged for the April 2025 finasteride alert; Henry Meds sued by Eli Lilly; the TRT cohort affected by class-wide testosterone labeling changes), and left others untouched (TrimRx, Eden, Hone Health, Function Health, and InsideTracker have no FDA enforcement actions, no active manufacturer lawsuits, and no state pharmacy enforcement). The same regulatory environment makes 'no FDA action and no state pharmacy enforcement' a meaningful trust signal, not just an absence.
The events, in chronological order
15 verified events from February 2025 through April 2026. Each entry has at least one primary-source link.
- FDA AlertFebruary 28, 2025
FDA issues class-wide labeling changes for testosterone products
Following review of the TRAVERSE clinical trial and postmarket ambulatory blood-pressure (ABPM) studies, the FDA informed sponsors of testosterone products of two material labeling changes. The Boxed Warning about increased risk of adverse cardiovascular outcomes was removed (TRAVERSE found no increased CV risk for men using testosterone for hypogonadism). New product-specific blood-pressure warnings were added based on ABPM studies showing class-wide blood-pressure increases. The Limitation of Use language for age-related hypogonadism was retained.
Why it matters
This is a meaningful regulatory upgrade for TRT prescribing: removing the cardiovascular boxed warning makes TRT easier to prescribe and reduces liability concerns for prescribers. The new blood-pressure warning is class-wide rather than provider-specific. Every TRT provider in our cohort (Hone Health, Defy Medical, Marek Health) operates under the updated labels; none was named in this action. The FDA also retained age-related-hypogonadism use restrictions, so this is not a green light for general 'optimization' prescribing.
Affected providers in our cohort
- Lawsuit FiledApril 23, 2025
Eli Lilly sues four telehealth compounders, including Henry Meds, over tirzepatide marketing
Case 4:25-cv-03536, Northern District of California
Eli Lilly and Company filed lawsuits against four telehealth companies (Fella Health, Willow Health, Henry Meds, Mochi Health) in the U.S. District Court for the Northern District of California. The lawsuit against Henry Meds (caption: Eli Lilly and Company v. Adonis Health, Inc. d/b/a Henry Meds) alleges deceptive marketing of compounded oral tirzepatide as 'personalized' and as equivalent to FDA-approved Mounjaro and Zepbound. Lanham Act and California consumer-protection claims.
Why it matters
If you're considering a compounded-tirzepatide provider, the manufacturer-litigation environment is real and ongoing. The lawsuit is about marketing language (personalization claims, equivalence claims to brand-name approved drugs) rather than product safety, but it indicates the manufacturer is actively contesting the way these products are sold. The Henry Meds case specifically remains active as of capture date.
Affected providers in our cohort
- FDA AlertApril 25, 2025
FDA safety alert on compounded topical finasteride (industry-wide)
The FDA issued a safety alert citing 32 reports of adverse events between 2019-2024 tied to compounded topical finasteride products, including suicidal ideation, anxiety, depression, erectile dysfunction, and persistent symptoms after discontinuation. The alert applies to compounders and telemedicine platforms broadly, not to any single named provider. Several telehealth platforms market compounded topical finasteride for hair loss.
Why it matters
This is industry-wide rather than provider-specific, but it informs the compounder-vendor management track record at any platform offering compounded topical finasteride. Ro markets compounded topical finasteride for hair loss, so the alert reflects on Ro's compounder-vendor management even though Ro was not specifically named in the alert. We weight this as a softer counterweight than direct warning letters, but worth knowing.
Affected providers in our cohort
- Partnership TerminatedJune 22, 2025
Novo Nordisk terminates collaboration with Hims & Hers
Novo Nordisk publicly terminated its April 2025 collaboration with Hims & Hers, citing concerns about Hims's continued mass compounding of semaglutide and what Novo described as deceptive marketing of compounded copycats of Wegovy. The termination ended the original commercial pathway for Hims to sell branded Wegovy and set the stage for the litigation that followed.
Why it matters
If you used Hims for branded Wegovy access in mid-2025 you would have been left without that pathway. The termination is now resolved by the March 2026 settlement (separate event below), and the post-settlement Hims is an authorized branded-only seller. But the timeline is recent enough that operational maturity questions remain.
Affected providers in our cohort
- Lawsuit FiledAugust 4, 2025
Novo Nordisk sues Mochi Health and 13 other compounders over semaglutide marketing and corporate practice of medicine
Case 5:25-cv-06563, Northern District of California
Novo Nordisk A/S et al filed a 14-defendant enforcement effort in U.S. District Court for the Northern District of California targeting telehealth companies, compounding pharmacies, and medical spas selling unapproved compounded semaglutide. The Mochi Health Corp. lawsuit (Case 5:25-cv-06563) adds an unlicensed-corporate-practice-of-medicine claim under California law alongside Lanham Act false-advertising claims, structurally broader than typical marketing-only litigation against compounders.
Why it matters
The corporate-practice-of-medicine claim is materially different from the Eli Lilly marketing-only cases against the same provider. If Novo prevails on that theory, it would constrain how Mochi structures its prescribing relationships going forward. Mochi is now defending two simultaneous federal lawsuits across both major manufacturers, more than any other provider in our marketplace cohort.
Affected providers in our cohort
- FDA Warning LetterSeptember 9, 2025
Twin FDA warning letters to Hims & Hers (compounded semaglutide marketing)
CMS #716567 (Hims), CMS #716825 (Hers)
The FDA issued two warning letters to Hims & Hers Health Inc., one to the Hims brand (CMS #716567) and one to the Hers brand (CMS #716825), both dated September 9, 2025. The agency cited claims like 'Same active ingredient as Ozempic and Wegovy' and 'Clinically proven ingredients' on compounded-semaglutide product pages as false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to brand-name approved products.
Why it matters
Direct FDA enforcement against Hims on the GLP-1 line. The letters are public and searchable on the FDA website. Hims has since wound down compounded GLP-1 advertising under the March 2026 Novo settlement, but the warning letters are recent enough to weigh in our scoring of the provider's licensure dimension.
FDA Warning Letter: Hims & Hers Health Inc. dba HimsFDA Warning Letter: Hims & Hers Health Inc. dba HersAffected providers in our cohort
- FDA Warning LetterSeptember 16, 2025
FDA issues 50+ warning letters to GLP-1 compounders and telehealth firms
Roughly one week after the Hims warning letters, the FDA issued more than 50 additional warning letters to U.S. and international companies that compound or manufacture GLP-1 products (semaglutide and tirzepatide). The enforcement focused on misleading marketing claims that compounded products were equivalent to FDA-approved brand-name medications. This was the largest single batch of compounded-GLP-1 enforcement actions to date.
Why it matters
The September 2025 enforcement wave reset the marketing constraints across the entire compounded-GLP-1 telehealth category. Providers in our cohort that did not receive a warning letter in this round (TrimRx, Eden, Ro, Henry Meds) cleared a meaningful regulatory bar; providers that did (Hims, MEDVi, Direct Meds, etc.) carry that signal in their licensure score.
Affected providers in our cohort
- Court RulingSeptember 24, 2025
Partial dismissal in Eli Lilly v. Henry Meds; personalization claim survives
Case 4:25-cv-03536, Document 62
Judge Jon S. Tigar (N.D. Cal.) issued an order granting in part and denying in part Henry Meds's motion to dismiss the Eli Lilly complaint. The personalization-marketing claim was allowed to proceed (Lilly's allegation that Henry Meds deceptively markets its compounded tirzepatide as 'personalized' when it is mass-produced); a separate 'safe and effective' marketing claim was dismissed. Eli Lilly was given until October 15, 2025 to file an amended complaint.
Why it matters
The Henry Meds litigation is not going away. The personalization claim surviving means Lilly's core marketing theory is plausible enough to proceed to discovery. For a current Henry Meds patient, the lawsuit is about marketing rather than product safety, but the outcome could affect how the compounded-tirzepatide product line is sold going forward.
Affected providers in our cohort
- Corporate EventNovember 19, 2025
Function Health closes $298M Series B at $2.5B valuation
Function Health announced a $298M Series B round led by Redpoint Ventures at a $2.5B valuation. Investors included a16z, Battery Ventures, NFDG (Nat Friedman and Daniel Gross), Roku founder Anthony Wood, and a roster of celebrity backers. Alongside the funding, Function announced a Medical Intelligence Lab effort to build a healthcare-focused generative AI model for personalized health insights. Function also lowered its annual membership from $499 to $365.
Why it matters
Operational and financial maturity is unusually relevant in DTC lab testing because the category includes a high failure rate of underfunded entrants. A $2.5B valuation backed by tier-one VCs gives Function meaningfully stronger operational footing than most cohort competitors. The accompanying $499 to $365 price reduction is the consumer-visible benefit; the AI lab is forward-looking but not yet a current-period feature. Worth knowing as a baseline-stability signal when comparing to smaller lab-testing platforms.
Affected providers in our cohort
- Lawsuit FiledFebruary 9, 2026
Novo Nordisk sues Hims over compounded oral semaglutide
Following the June 2025 termination of the Hims partnership, Novo Nordisk filed suit against Hims & Hers over compounded oral semaglutide products. The lawsuit alleged that Hims continued to mass-market unapproved compounded copies of Wegovy and Ozempic in violation of federal law. Hims stock fell roughly 18% on the news.
Why it matters
The lawsuit set the table for the March 2026 settlement that resolved the Hims-Novo dispute. For Hims patients during this window, ongoing access to compounded GLP-1 was uncertain; for the post-settlement Hims, the lawsuit is resolved and the platform is branded-only.
Affected providers in our cohort
- Press InvestigationFebruary 20, 2026
KING 5 News investigation: Aequita Pharmacy (Mochi-affiliated) using unlicensed day laborers and Otter Pops for cold-chain shipping
KING 5 News (Seattle ABC affiliate) aired an investigative report with on-camera evidence of whistleblower allegations against Aequita Pharmacy, the Kirkland WA compounding pharmacy that fills Mochi Health prescriptions. Allegations: starting in July 2025, Aequita managers hired day laborers from Home Depot and Lowes parking lots to perform sterile compounding without proper training or supervision; medication shipments used frozen children's Otter Pops popsicles as cold-chain refrigerant instead of medical-grade ice packs.
Why it matters
Cold-chain shipping with consumer-grade ice and unlicensed sterile-compounding workers are not abstract regulatory concerns. Semaglutide and tirzepatide are biologics whose potency degrades with temperature excursions; sterile compounding without proper procedures introduces contamination risk. The press coverage was substantiated by subsequent WA State enforcement (next event), making this materially different from unverified blog allegations.
Affected providers in our cohort
- State Regulatory ActionFebruary 23, 2026
Washington State Notice of Immediate Jeopardy on Aequita Pharmacy (Mochi-affiliated)
The Washington State Department of Health Pharmacy Quality Assurance Commission issued a Limited Stop Service against Aequita Pharmacy that ultimately escalated to a Notice of Immediate Jeopardy, the strongest pharmacy enforcement category. Aequita could not compound, dispense, deliver, or distribute compounded products in Washington state until the action was resolved. Cited deficient sterile-compounding practices including untrained staff, inadequate supervision, and failure to adhere to sterile-compounding procedures designed to ensure product integrity and patient safety. Aequita's listed owner pharmacist Nathan Kenney signed an Agreed Order in July 2025 that did not contest the findings.
Why it matters
This is the most material product-quality regulatory action in our entire marketplace cohort. It is structurally different from manufacturer marketing-claim litigation: a state pharmacy regulator substantiated, on the record, that the compounding pharmacy filling Mochi prescriptions was operating with unlicensed workers performing sterile compounding and improper cold-chain shipping. We weight this much more heavily than a marketing lawsuit when scoring product quality and licensure.
Washington State DOH: Pharmacy Quality Assurance Commission Limited Stop ServicePartnership for Safe Medicines: state investigates whistleblower allegationsAffected providers in our cohort
- FDA Warning LetterMarch 3, 2026
FDA issues 30 warning letters to telehealth firms (second wave)
The FDA announced 30 warning letters to telehealth companies for false or misleading marketing of compounded GLP-1 products. This was the second major enforcement wave against telehealth marketing of compounded GLP-1, after the September 2025 round. Companies named in this wave included Lovely Meds, Hello Cake, MEDVi, and others; major branded platforms (Ro, Hims) and compounded specialists in our cohort (TrimRx, Eden, Henry Meds) were not named in this round.
Why it matters
Providers in our cohort that cleared both the September 2025 and March 2026 enforcement waves (TrimRx, Eden, Ro, Hone Health, Function Health, InsideTracker) have a meaningful regulatory signal: not just one round of FDA scrutiny but two, without enforcement against them.
- SettlementMarch 9, 2026
Novo Nordisk and Hims settle; Hims becomes authorized branded GLP-1 seller
Novo Nordisk and Hims & Hers reached a settlement: Novo dropped its lawsuit, Hims became an authorized seller of Wegovy (injection and oral pill) and Ozempic, and Hims agreed to stop advertising compounded GLP-1 medications. The settlement marked the end of the multi-month commercial dispute between the two companies and re-established the commercial pathway for Hims to sell branded Wegovy.
Why it matters
Post-settlement Hims is a branded-only platform for new patients in this category. If you considered Hims for compounded GLP-1, that pathway is closed; the platform now competes on branded GLP-1 with insurance pathway support, which puts it head-to-head with Ro on the same product line.
Affected providers in our cohort
- Corporate EventApril 1, 2026
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics announced the acquisition of Tally Health to accelerate epigenetics-driven health and longevity products. Tally Health remains a standalone consumer brand under the new parent per the acquisition announcement. The deal followed a period of operational complaints on Trustpilot about result-delivery delays running 9+ weeks against the company's advertised 2-4 weeks; the post-acquisition operational impact is not yet visible in public reviews.
Why it matters
Corporate transitions can affect operations meaningfully. For current Tally Health customers, the brand and product are unchanged, but the operational pipeline now sits under Infinite Epigenetics's resources. The acquisition could improve the result-delivery delays that drove recent negative reviews, or it could introduce its own friction during integration. We treat this as a watch-list item rather than a clear positive or negative signal.
Affected providers in our cohort
Get an email when this timeline updates
One email per material regulatory event affecting providers in our marketplace cohort. No marketing. One-click unsubscribe in every email. Or subscribe via RSS at /providers/regulatory-timeline/feed.xml.
We collect your email and the topic you subscribed to, nothing else. One-click unsubscribe in every email. Topic-specific subscriptions only, never marketing.
How this affects choosing a provider today
Each provider profile cross-references the events above in its regulatory-history section, with the same primary-source links. The directory ranks every provider on a public six-dimension rubric, and category landing pages explain what to look for in each segment of the market.
We re-verify the regulatory landscape quarterly. If you spot an event we missed or one that needs updating, get in touch.